Global Hyperglycemia Medicines Market (By Product- Injectable Drugs, Oral Drugs, Insulin Pumps, Insulin Therapies, Insulin Injection Devices and Others. By Application- Type I Diabetes, Type II Diabetes and Others) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025

December 2017 | 107 pages | ID: G5A97235CD0EN
Sheer Analytics and Insights Private Limited

Abstracts

The report covers the analysis and forecast of the hyperglycemia medicines market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Mn).

The study provides a detailed view of the hyperglycemia medicines market, by segmenting it based on by product, by application and regional demand. Increasing incidents of diabetes across the globe, creates a huge growth opportunity for hyperglycemia medicines in the nearby future. Moreover, product development by leading key vendors and their huge presence all over the world makes the market more demanding during the forecast period upto 2025.

Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by product, and application in all regions. These include different business strategies adopted by the leading players and their recent developments.

A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the Hyperglycemia medicines market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the hyperglycemia medicines market.

The report provides the size of the hyperglycemia medicines market in 2016 and the forecast for the next nine years up to 2025. The size of the global Hyperglycemia medicines market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been taken into account in estimating the growth of the global market.

Market estimates for this study have been based on revenue being derived through regional pricing trends. The Hyperglycemia medicines market has been analyzed based on expected demand. We have used the bottom-up approach to estimate the global revenue of the hyperglycemia medicines market, split into regions. Based on, product, and applications we have summed up the individual revenues from all the regions to achieve the global revenue for hyperglycemia medicines. Companies were considered for the market share analysis, based on their innovation and application and revenue generation. In the absence of specific data related to the sales of hyperglycemia medicines several privately held companies, calculated assumptions have been made in view of the company’s penetration and regional presence.

The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market. Key players profiled in the report include Medtronic Inc., Johnson & Johnson, Dexcom Inc., Abbott Laboratories, Bayer Healthcare AG and few more.

The global hyperglycemia medicines market has been segmented into:

Global Hyperglycemia Medicines Market: By Product

• Injectable Drugs
• Oral Drugs
• Insulin Pumps
• Insulin Therapies
• Insulin Injection Devices
• Others

Global Hyperglycemia Medicines Market: By Applications

• Type I Diabetes
• Type II Diabetes
• Others

Global Hyperglycemia Medicines Market: By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• U.K.
• France
• Germany
• Italy
• Rest of Europe
• Asia Pacific
• India
• China
• Japan
• Rest of Asia Pacific
• Middle East and Africa
• South Africa
• Rest of Middle East and Africa
• Latin America
• Brazil
• Rest of Latin America

Contents

1 INTRODUCTION

1.1 MARKET SEGMENTATION

2 RESEARCH METHODOLOGY

2.1 ECOSYSTEM OF HYPERGLYCEMIA MEDICINES MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 GLOBAL HYPERGLYCEMIA MEDICINES MARKET SNAPSHOT
3.2 GLOBAL HYPERGLYCEMIA MEDICINES MARKET REVENUE, 2017– 2025(US$ MN)

4 MARKET OVERVIEW

4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS

5 GLOBAL HYPERGLYCEMIA MEDICINES MARKET, BY PRODUCT

5.1 OVERVIEW
5.2 INJECTABLE DRUGS
5.3 ORAL DRUGS
5.4 INSULIN PUMPS
5.5 INSULIN THERAPIES
5.6 INSULIN INJECTION DEVICES
5.7 OTHERS

6 GLOBAL HYPERGLYCEMIA MEDICINES MARKET, BY APPLICATION

6.1 OVERVIEW
6.2 TYPE I DIABETES
6.3 TYPE II DIABETES
6.4 OTHERS

7 GLOBAL HYPERGLYCEMIA MEDICINES MARKET, BY GEOGRAPHY

7.1 NORTH AMERICA
  7.1.1 MARKET DYNAMICS
    7.1.1.1 DRIVERS
    7.1.1.2 RESTRAINS
    7.1.1.3 OPPORTUNITY
  7.1.2 U.S.
  7.1.3 CANADA
  7.1.4 MEXICO
7.2 EUROPE
  7.2.1 MARKET DYNAMICS
    7.2.1.1 DRIVERS
    7.2.1.2 RESTRAINS
    7.2.1.3 OPPORTUNITY
  7.2.2 U.K.
  7.2.3 FRANCE
  7.2.4 GERMANY
  7.2.5 SPAIN
  7.2.6 REST OF EUROPE
7.3 ASIA PACIFIC
  7.3.1 MARKET DYNAMICS
    7.3.1.1 DRIVERS
    7.3.1.2 RESTRAINS
    7.3.1.3 OPPORTUNITY
  7.3.2 INDIA
  7.3.3 CHINA
  7.3.4 JAPAN
  7.3.5 REST OF ASIA PACIFIC
7.4 MIDDLE EAST AND AFRICA
  7.4.1 MARKET DYNAMICS
    7.4.1.1 DRIVERS
    7.4.1.2 RESTRAINS
    7.4.1.3 OPPORTUNITY
  7.4.2 SOUTH AFRICA
  7.4.3 REST OF MIDDLE EAST AND AFRICA
7.5 LATIN AMERICA
  7.5.1 MARKET DYNAMICS
    7.5.1.1 DRIVERS
    7.5.1.2 RESTRAINS
    7.5.1.3 OPPORTUNITY
  7.5.2 BRAZIL
  7.5.3 REST OF LATIN AMERICA

8 COMPETATIVE LANDSCAPE

8.1 OVERVIEW
8.2 NEW PRODUCT LAUNCHES

9 GLOBAL HYPERGLYCEMIA MEDICINES MARKET, BY COMPANY

9.1 INTRODUCTION
9.2 ABBOTT LABORATORIES
  9.2.1 BUSINESS OVERVIEW
  9.2.2 PRODUCTS & SERVICES
  9.2.3 KEY STRATEGY
  9.2.4 RECENT DEVELOPMENTS
  9.2.5 SWOT ANALYSIS
9.3 DEXCOM INC.
  9.3.1 BUSINESS OVERVIEW
  9.3.2 PRODUCTS & SERVICES
  9.3.3 KEY STRATEGY
  9.3.4 RECENT DEVELOPMENTS
  9.3.5 SWOT ANALYSIS
9.4 JOHNSON & JOHNSON
  9.4.1 BUSINESS OVERVIEW
  9.4.2 PRODUCTS & SERVICES
  9.4.3 KEY STRATEGY
  9.4.4 RECENT DEVELOPMENTS
  9.4.5 SWOT ANALYSIS
9.5 BAYER HEALTHCARE AG
  9.5.1 BUSINESS OVERVIEW
  9.5.2 PRODUCTS & SERVICES
  9.5.3 KEY STRATEGY
  9.5.4 RECENT DEVELOPMENTS
  9.5.5 SWOT ANALYSIS
9.6 GLAXOSMITHKLINE PLC
  9.6.1 BUSINESS OVERVIEW
  9.6.2 PRODUCTS & SERVICES
  9.6.3 KEY STRATEGY
  9.6.4 RECENT DEVELOPMENTS
  9.6.5 SWOT ANALYSIS
9.7 MEDTRONIC INC.
  9.7.1 BUSINESS OVERVIEW
  9.7.2 PRODUCTS & SERVICES
  9.7.3 KEY STRATEGY
  9.7.4 RECENT DEVELOPMENTS
  9.7.5 SWOT ANALYSIS
9.8 AMYLIN PHARMACEUTICALS INC.
  9.8.1 BUSINESS OVERVIEW
  9.8.2 PRODUCTS & SERVICES
  9.8.3 KEY STRATEGY
  9.8.4 RECENT DEVELOPMENTS
  9.8.5 SWOT ANALYSIS
9.9 MERCK & COMPANY INC.
  9.9.1 BUSINESS OVERVIEW
  9.9.2 PRODUCTS & SERVICES
  9.9.3 KEY STRATEGY
  9.9.4 RECENT DEVELOPMENTS
Swot Analysis